The GSK Oncology International Ethnic Research Initiative (GSK ERI) was established to address the lack of breast cancer data in these populations, through the provision of grants for independent, non-clinical research projects.
During the event, Dr. Nagi spoke about the current prevalence and burden of breast cancer in the region. He also educated the audience on how his research would help in understanding the cause of the number one fatal disease among women. In addition, his presentation delved into the perceived link between ethnicity and breast cancer.
"I feel tremendously honored to be awarded this prestigious grant. This is not only an achievement for me, but for the entire medical practice in the region. This initiative couldn't have come at a more opportune moment as recent figures indicate that of the 3.2 billion women in the world afflicted with cancer, 90% of them are non-Caucasian. Over the last few decades, the incidence of breast cancer has grown rapidly in many developing countries compared to developed countries, where the growth is slower," Dr. Nagi added.
The grant is provided to support independent, non-clinical research focused on improving understanding of the epidemiology and genetics of breast cancer in ethnically diverse populations of the world.
Dr. Nagi further elaborated that in developing countries many women lack access to preventive and curative services. "There is a paucity of clinical research and reliable epidemiological data. Treatment guidelines are based on research collected from the Western world."
With over 20 years experience, Dr. Nagi is currently the Exclusive Director of the National Oncology Centre (NOC) in Yemen. He is well versed in the following medical procedures: bone marrow aspiration and biopsy examination, fine needle aspiration (FNA) Cytology, Lymph Node, Liver and Splenic biopsy and aspiration as well as Body Cavity Paracenthesis with lumber puncture.
Browse
related articles
Middle East doctor awarded international ethnic research grant to study relationship between ethnicity and breast cancer
- Yemen: Monday, April 06 - 2009 at 12:30
- PRESS RELEASE
Related content
Dr. Nadeem Mohammad Nagi, Director at National Oncology Centre - Yemen Republic is amongst the first researchers to be awarded funding as part of a new initiative which aims to advance understanding of breast cancer in ethnically diverse (non-Caucasian) populations.
Article Options
Log in to request more information from GlaxoSmithKline
Posted by Rana MesbahMonday, April 06 - 2009 at 12:30 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Notes and Media Contacts »
About the GSK ERI:
The GSK ERI was established to provide grants to support independent, non-clinical research focused on improving understanding of the epidemiology and genetics of breast cancer in ethnically diverse (non-Caucasian) populations of the world. Grants will be provided annually to investigators in Latin America, Asia, Middle East and Africa (or in other countries with ethnically diverse populations, excluding the USA and Europe).
Research projects considered may include breast cancer epidemiology; ethnicity; genetics; risk assessment; biomarkers of risk or other factors causing or contributing to breast cancer; and other aspects of non-clinical research.
It is believed that the GSK ERI is the first international research grant programme dedicated to non-clinical, breast cancer research in ethnically diverse (non-Caucasian) women, outside the USA and Europe.
GSK is committed to promoting excellence in scientific research. Every effort has gone into ensuring that the GSK ERI is conducted in an ethical manner with the independence of the applications review rigorously maintained. The application review and final selection of grant recipients is conducted by an independent Expert Steering Committee, over which GSK has no influence.
GSK in Oncology:
GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector.
Our worldwide research in oncology includes collaborations with more than 160 cancer centres. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
For more information, please contact:
Dr. Aly Ziwar
Medical and Regulatory Director
GSK Gulf and Near East
Tel: 00971 4 4037129
or
Rosalie Ghostine
Oncology Business Unit Head
GSK Gulf and Near East
Tel: 00971 4 4037123
The GSK ERI was established to provide grants to support independent, non-clinical research focused on improving understanding of the epidemiology and genetics of breast cancer in ethnically diverse (non-Caucasian) populations of the world. Grants will be provided annually to investigators in Latin America, Asia, Middle East and Africa (or in other countries with ethnically diverse populations, excluding the USA and Europe).
Research projects considered may include breast cancer epidemiology; ethnicity; genetics; risk assessment; biomarkers of risk or other factors causing or contributing to breast cancer; and other aspects of non-clinical research.
It is believed that the GSK ERI is the first international research grant programme dedicated to non-clinical, breast cancer research in ethnically diverse (non-Caucasian) women, outside the USA and Europe.
GSK is committed to promoting excellence in scientific research. Every effort has gone into ensuring that the GSK ERI is conducted in an ethical manner with the independence of the applications review rigorously maintained. The application review and final selection of grant recipients is conducted by an independent Expert Steering Committee, over which GSK has no influence.
GSK in Oncology:
GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector.
Our worldwide research in oncology includes collaborations with more than 160 cancer centres. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
For more information, please contact:
Dr. Aly Ziwar
Medical and Regulatory Director
GSK Gulf and Near East
Tel: 00971 4 4037129
or
Rosalie Ghostine
Oncology Business Unit Head
GSK Gulf and Near East
Tel: 00971 4 4037123
Disclaimer »
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
